ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effect of Quercetin in Sarcoidosis

This study has been completed.

Sponsors and Collaborators: Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT00402623
  Purpose

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.


Condition Intervention
Sarcoidosis
Dietary Supplement: quercetin
Other: placebo

MedlinePlus related topics:   Antioxidants    Sarcoidosis    Stress   

ChemIDplus related topics:   Quercetin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • antioxidant status after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • inflammatory status after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • plasma quercetin concentration after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • plasma malondialdehyde (MDA) levels after 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Enrollment:   18
Study Start Date:   January 2006
Study Completion Date:   January 2006
Primary Completion Date:   January 2006 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Placebo Comparator
placebo
Other: placebo
2: Active Comparator
quercetin (food supplement)
Dietary Supplement: quercetin
1000 mg quercetin within 24 hours

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
  • no smoking
  • no treatment

Exclusion Criteria:

  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  • use of food supplements or vitamins
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00402623

Locations
Netherlands
Maastricht University    
      Maastricht, Netherlands, 6200 MD

Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Investigators
Study Chair:     Aalt Bast, PhD     Maastricht University Medical Center    
Principal Investigator:     Agnes W Boots, PhD     Maastricht University Medical Center    
Study Director:     Guido R Haenen, PhD     Maastricht University Medical Center    
  More Information


Responsible Party:   Maastricht University ( Dr. A.W. Boots )
Study ID Numbers:   MEC 05.142.5
First Received:   November 20, 2006
Last Updated:   February 21, 2008
ClinicalTrials.gov Identifier:   NCT00402623
Health Authority:   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
sarcoidosis  
quercetin  
supplementation  
oxidative stress  
inflammation  

Study placed in the following topic categories:
Lymphatic Diseases
Stress
Sarcoidosis
Lymphoproliferative Disorders
Quercetin
Inflammation

Additional relevant MeSH terms:
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers